Eisai US

Eisai US is a prominent company in the biotechnology, health care, and pharmaceutical industries. Founded in 1995, it is the U.S. pharmaceutical subsidiary of Tokyo-based Eisai Co., Ltd. The company has a focused approach, primarily operating in the therapeutic areas of oncology and neurology, particularly in dementia-related and neurodegenerative diseases. Eisai is dedicated to patient care and is committed to discovering and developing innovative therapies to meet unmet medical needs.

With a fully integrated pharmaceutical business, Eisai operates in two global business groups: oncology and neurology, with capabilities in discovery, development, and marketing. The company's U.S. headquarters, commercial and clinical development organizations are located in New Jersey, while its discovery labs are in Massachusetts and Pennsylvania. Additionally, its global demand chain organization resides in Maryland and North Carolina. For more information, visit www.eisai.com/US.

Eisai's commitment to human health care (hhc) underscores its dedication to putting patients and their families first, aiming to enhance the benefits that healthcare provides. The company's slogan "Breaking through in the therapeutic areas of oncology and neurology" reflects its ambitious and innovative approach in the pharmaceutical field.

It is important to note that comments and posts by users on the company's site are not created or controlled by Eisai Inc. and the company holds no responsibility for such content.